Study 1199.223 LUME BioNIS
Research type
Research Study
Full title
A non-interventional biomarker study in patients with Non-Small Cell Lung Cancer (NSCLC) of adenocarcinoma tumour histology eligible for treatment with Vargatef® according to the approved label.
IRAS ID
196702
Contact name
Joanne Morrison
Contact email
Sponsor organisation
Boehringer Ingelheim
Duration of Study in the UK
4 years, 1 months, 15 days
Research summary
Patients that are assigned to treatment with Vargatef® as part of their routine treatment according to the approved label are eligible for participation in the study. This is a Non-interventional, multi-country, multi-site study based on newly collected data in patients that are assigned to receive Vargatef® as part of their routine treatment according to the approved label for the first time. Patients will be followed up until death, lost to follow-up, withdrawal of consent, or until required number of OS events has occurred, whichever occurs first.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
16/NW/0130
Date of REC Opinion
6 Apr 2016
REC opinion
Further Information Favourable Opinion